From: Therapeutic role of curcumin and its novel formulations in gynecological cancers
Type of curcumin | Dose | Main target (s) | Main effect (s) | Model (in vivo/in vitro/human) | Cell line | Ref |
---|---|---|---|---|---|---|
Curcumin | 20 μM for 72h | N-cadherin, Vimentin, Slug, PIR, Pirin | Inhibition of cancer cell growth, migration, invasion Inhibition of angiogenesis Induction of apoptosis and necrosis Induction of cell cycle arrest Increased radiosensitization of cancer cells | In vitro | SiHa | [63] |
2.5, 5 μmol/L In vivo (150-200 μL) | Notch-1, NF-κB, VEGF | In vivo In vitro | Me180 | [57] | ||
5× IC50 (34.23 μM/ml) | Wnt/β-catenin NF-kB pathway | In vitro | HeLa | [64] | ||
13 μM | BRCA1, p-p53, p-H2A.XSer140 | In vitro | HeLa | [59] | ||
IC50= 16.52 μM | ROS, p21, Bax, p53, ROS, p21, Bax | In vitro | HeLa | [65] | ||
10 μM In vivo (4 mg/kg) | - | In vitro In vivo | HeLa | [66] | ||
10 μM | TGF-β activates Wnt/β-catenin signaling pathway |  | In vitro | SiHa HeLa | [67] | |
10 μM | NF-κB-p53-caspase-3 pathway | Curcumin improves the paclitaxel-induced apoptosis of cervical cancer cell lines infected with HPV. | In vitro | CaSki HeLa | [68] | |
5 μM | - | Curcumin-induced apoptosis and oxidative stress | In vitro | HeLa | [69] | |
1000 and 1500 mg/kg for 30 days | - | Curcumin inhibits angiogenesis and tumor growth mediated by decreasing the expression of VEGF, EGFR, and COX-2. | In vivo | - | [62] | |
50 μM | - | Curcumin sensitizes cervical cancer cells to cisplatin-based chemotherapy through inhibition of Pgp1and MRP1. | In vitro | SiHa SiHaR | [70] | |
20 μM | - | Curcumin induced ER stress-mediated apoptosis via increasing of ROS generation and by activation of CHOP | In vitro | C33A CaSki HeLa ME180 | [61] | |
IC50: 17 μM (HeLa), 12 μM (ME-180), 51 μM (SiHa), 21 μM (SW756) Dose: 50 μM for 48h | - | Curcumin-based vaginal cream effectively eradicates HPV positive cervical cancer cells. | In vitro | HeLa ME-180 SiHa SW756 | [71] | |
10 and 25 μM | Akt, MAPK, and AP-1 pathways | Curcumin potentiates the antitumor effects of paclitaxel by downregulating Akt, MAPK, and AP-1 pathways and decreasing the transcription of NF-kB target genes. | In vivo | - | [72] | |
25 and 50 μM | - | Curcumin can induce apoptosis by inhibition of PCNA, Cyclin D1, telomerase, and p16 and by activation of p53 and p73 in HPV-negative cancer cells pretreated with estradiol. | In vivo | HeLa SiHa CaSki C33A | [54] | |
50 and 100 μM for 24h | Apoptosis and inflammatory pathways | Curcumin mediates apoptosis in SiHa and HeLa cell lines. Curcumin can act as an anti-proliferative and anti-inflammatory agent for Ca Ski, HeLa, and SiHa cells | In vitro | HeLa SiHa CaSki | [73] | |
15 μM for 48h | - | Curcumin exhibits antitumor activity against cervical cancer cells. Curcumin downregulates PGE2 expression. | In vitro | HeLa | [56] | |
10 μM for 8h | MAP kinase pathway | Curcumin is a potent radiosensitizer by increasing ROS production and overacts the MAP kinase pathway. | In vitro | HeLa SiHa | [74] | |
10μMCombined curcumin (10μM) ultrasound (8 s of 5-7.5 MHz) | - | Curcumin can lead to necrosis in cervical cancer cell lines. Combined curcumin ultrasound enhances necrosis in cervical cancer cell lines. | In vitro | HeLa SiHa C33A | [60] | |
ST06-AgNPs | IC50: 1μM Dose: 1-2 μM Dose: 5 mg/kg body weight for 30 days (In vivo) | - | Inhibited cancer cell growth | In vivo In vitro | HeLa | [75] |
Folic acid-modified liposomal curcumin | IC50: 1.47 μg/mL for free curcumin IC50: 0.45 μg/mL for (DSPE)-PEG2000-FA-LPs/CUR Dose: 25 mg/kg for 51 days (In vivo) | - | Anti-proliferative effects | In vitro In vivo | HeLa | [76] |
4-Bromo-4'-chloro pyrazoline | IC50: 8.7μg/ml for Chloro bromo analogIC50: 42.24 μg/mL for curcumin | - | Apoptosis induction | In vitro | HeLa | [77] |
Chloro and bromo-pyrazolecurcumin | IC50: 14.2 and 18.6 μg/ml for Chloro derivative and bromo analog, respectively. IC50: 42.4 μg/ml for curcumin | - | Apoptosis induction | In vitro | HeLa | [78] |
Curcumin-loaded microbubble | 1.25–40 μM | - | Decreased cancer cell viability | In vitro | HeLa | [79] |
Bisdemethoxycurcumin | 5μM for 24 and 48h | NF-kB, MMP-2 and -9 Pathways | Anti-migration and anti-invasion effects | In vitro | HeLa | [80] |
Curcumin-PDT | - | Notch signaling pathway | Necrosis induction | In vivo | Me180 | [81] |
Curcumin-loaded micells | 50 μg/mL | - | Increased cytotoxicity against cancer cells Apoptosis induction | In vitro | HeLa HepG2 NIH-3T3 | [82] |
Demethoxycurcumin | 15 μM IC20: 7.5 μM | NF-κB Pathways | Anti-migration and anti-invasion effects | In vitro | HeLa | [83] |
Curcumin-loaded chitosan nanoparticles | 24μM | - | Apoptosis induction Anti-proliferative effects Showed better chemopreventive and chemotherapeutic effects than curcumin | In vitro | SiHa | [84] |
Difluorinated curcumin Folate decorated bovine serum albumin (FA-BSA) nanoparticles loaded with Difluorinated curcumin (CDF) (FA-BSA-CDF) | Dose: 2 μM (Difluorinated curcumin and FA-BSA-CDF) Dose: 0.5 μM (Combination) | - | Synergistic anticancer effectsApoptosis induction | In vitro | HeLa SKOV3 | [85] |
Curcumin-nanoemulsion | 20 to 40μM | - | Apoptosis induction | In vitro | CasKi SiHa HaCaT | [86] |
Curcumin-Loaded TPGS/F127/P123 Mixed Polymeric Micelles | Dose: 8 μg/mL Dose: 25 mg/kg for 11 times in 2 days (In vivo) | - | Increased cytotoxicity against cancer cells Induction of apoptosis and cell cycle arrest | In vivo In vitro | HeLa NIH3T3 cells | [87] |
Curcumin-loaded chitosan-alginate-sodium tripolyphosphate nanoparticles | 50 μg/mL | Bax , Bcl-2 | Anti-proliferative effects Apoptosis induction | In vitro | HeLa | [88] |
Folic acid conjugated polymeric micelles loaded with a curcumindifluorinated | 0.47 ± 0.14 μM | PTEN, NF-κB | Apoptosis induction | In vitro | HeLa | [89] |
Curcumin-loaded chitosan Nanoparticles | 108 μM | Bax, Bcl-2 | Apoptosis induction | In vitro | SiHa Hela Caski C33a | [90] |
Tetrahydrocurcumin | 100, 300, or 500 mg/kg body weight for 30 days | COX-2, EGFR, p-ERK1&2, p-AKT, Ki-67 | Apoptosis induction Antitumor Effect | In vivo | CaSki | [91] |
Nano-Curcumin | 20 and 25 μM for 48h | Anti-survival pathways | Inhibited cancer cell growth Induction of apoptosis and cycle cell arrest | In vitro | SiHa, Caski | [19] |
Tetrahydrocurcumin | 50, 100 mg/kg | - | Inhibited cancer cell growth Anti-angiogenesis effects | In vivo In vitro | CaSki | |
Curcumin (CCM)-loaded nanoscale zeolitic imidazolate framework-8 (CCM@NZIF-8) nanoparticles | Dose: 1-10 μg/mL Dose: 2.5 mg/kg body weight for 6 times in 2 days (In vivo) | - | Anti-proliferative effects Showed higher efficacy than free curcumin | In vivo In vitro | HeLa | [94] |
Curcumin-loaded cationic liposome | IC50: 16, 21 μM | - | Apoptosis induction | In vitro | HeLa SiHa | [95] |